CARDINAL HEALTH INC
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
CAH$271.72+1.5%Stored close · as of Nov 6, 2026
What changed in Management’s Discussion and Analysis?
Read the current filingPrevious report: 10-Q
Period ended 2026-03-31; filed 2026-04-30.
0000721371-26-000018
Item 2. Management's Discussion and Analysis of Financial Condition and Results of OperationsExplanation and Reconciliation of Non-GAAP Financial MeasuresCurrent report: 10-Q
Period ended 2026-09-30; filed 2026-11-05.
0000721371-26-000043
Management's Discussion and Analysis of Financial Condition and Results of Operations About Cardinal HealthOverview of Consolidated ResultsSignificant Developments in Fiscal 2027 and TrendsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 155 previous paragraphs and 42 current paragraphs.
10 unchanged; 11 reworded; 19 added; 130 removed; 4 previous and 2 current paragraphs rearranged.
Tables are not compared: 38 previous and 8 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (19)
Current report
About Cardinal Health
Current report
Cardinal Health, Inc., an Ohio corporation formed in 1979, is a global healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. We provide pharmaceuticals and medical products and cost-effective services and solutions that enhance the healthcare system and supply chain efficiency. We connect patients, providers, payers, pharmacists, and manufacturers for integrated care coordination.
Current report
We report our financial results in two reportable segments: Pharmaceutical and Specialty Solutions ("Pharma") segment and Global Medical Products and Distribution ("GMPD") segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other, which is comprised of Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight® Logistics.
Current report
Our Pharma segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; repackages generic pharmaceuticals and over-the-counter healthcare products; and includes our managed services organization ("MSO") platforms for physician offices.
Current report
Our GMPD segment manufactures, sources, and distributes Cardinal Health brand medical, surgical, and laboratory products, which are sold in the United States, Canada, Europe, Asia, and other markets. This segment also distributes a broad range of medical, surgical, and laboratory products known as national brand products to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers in the United States and Canada.
Current report
Other Operating Segments
Current report
Our Nuclear and Precision Health Solutions operating segment operates nuclear pharmacies and manufacturing facilities, which manufacture, prepare, and deliver radiopharmaceuticals for use in nuclear imaging, theranostics, and other procedures in hospitals and physician offices. This segment also contract manufactures radiopharmaceutical isotopes and treatments and holds the rights to manufacture and distribute Lymphoseek®, a radiopharmaceutical diagnostic imaging agent.
Current report
Our at-Home Solutions operating segment has two main businesses: Edgepark, including Advanced Diabetes Supply Group ("ADS"), directly providing medical supplies to patients with chronic conditions in the home; and at-Home, a business-to-business distribution service that delivers medical supplies and over-the-counter products to home medical equipment providers, home health and hospice agencies, and e-commerce providers.
Current report
Our OptiFreight® Logistics operating segment supports the shipping and logistics needs of healthcare providers by optimizing direct shipments through integrated technology solutions. This operating segment serves hospitals, pharmacies, labs, and surgery centers.
Current report
Revenue increased 5 percent from the prior-year quarter to $67.5 billion due to branded and specialty pharmaceutical sales growth from existing customers.
Current report
GAAP operating earnings for the three months ended September 30, 2026 increased 13 percent from the prior-year quarter to $753 million, primarily due to the increased contributions from branded and specialty pharmaceutical products and the performance of our generics program, partially offset by an increase in acquisition-related costs.
Current report
Non-GAAP operating earnings for the three months ended September 30, 2026 increased 17 percent from the prior-year quarter to $1.0 billion, primarily due to the increased contributions from branded and specialty pharmaceutical products and the performance of our generics program.
Current report
Pharmaceutical and Specialty Solutions Segment
Current report
An April 2026 proclamation issued by the President of the United States imposed tariffs on imports of branded pharmaceutical products and associated ingredients imported into the United States. If pharmaceutical manufacturers raise their prices or stop importing certain products, we could experience increased costs or supply disruptions which may impact our financial results.
Current report
With respect to GLP-1 medications, we experienced increased demand during the three months ended September 30, 2026, which positively impacted our Pharma segment revenue and consolidated revenue; however, increased GLP-1 sales did not meaningfully contribute to segment profit. Demand growth for GLP-1 medications began to moderate in fiscal year 2026 and we expect future demand growth moderation to continue; however, demand for these medications is unpredictable.
Current report
Additionally, while generic pharmaceutical products are not currently subject to U.S. tariffs, in July 2026, the President issued a statement indicating that generic pharmaceutical products will be subject to 100% tariffs beginning in 2028 and 200% tariffs beginning in 2029. There remains significant uncertainty about the ultimate implementation of this proposal; however, these potential tariffs may impact our costs or decrease available supply, which could impact Pharma segment profit and consolidated operating earnings.
Current report
The conflict in Iran has resulted in higher than anticipated costs for fuel and transportation across the enterprise as well as products manufactured or distributed by our GMPD segment. We may not be successful at offsetting these increased prices through cost-savings measures or increasing prices to customers. If we are not able to offset these increased prices, profit may be negatively impacted to a greater extent than initially expected.
Removed paragraphs (130)
Previous report
The discussion and analysis presented below is concerned with material changes in financial condition and results of operations, including amounts and certainty of cash flows from operations and from outside sources, between the periods specified in our condensed consolidated balance sheets at March 31, 2026 and June 30, 2025, and in our condensed consolidated statements of earnings and our condensed consolidated statements of cash flows for the three and nine months ended March 31, 2026 and 2025. All comparisons presented are with respect to the prior-year period, unless stated otherwise. The discussion and analysis in this Form 10-Q should be read in conjunction with the MD&A included in our 2025 Form 10-K.
Previous report
Revenue for the three months ended March 31, 2026 increased 11 percent to $60.9 billion from the comparative prior-year quarter, primarily due to branded and specialty pharmaceutical sales growth from existing customers. Revenue for the nine months ended March 31, 2026 increased 17 percent to $190.6 billion from the comparative prior-year period, primarily due to branded and specialty pharmaceutical sales growth from existing and new customers.
Previous report
GAAP operating earnings for the three and nine months ended March 31, 2026 decreased 30 percent to $509 million and increased 2 percent to $1.9 billion from the comparative prior-year periods, respectively. GAAP operating earnings for the three and nine months ended March 31, 2026 was unfavorably impacted by the $184 million pre-tax non-cash goodwill impairment charge related to the Navista & ION reporting unit within the Pharma segment recognized in the current quarter, the $106 million and $165 million of net recoveries in class action antitrust litigation recognized in the comparative prior-year periods, respectively, and higher cash and share-based compensation costs resulting from the timing of acquisitions within The Specialty Alliance. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&A and Note 4 of the "Notes to the Condensed Consolidated Financial Statements" for further information on the goodwill impairment.
Previous report
Non-GAAP operating earnings for the three and nine months ended March 31, 2026 increased 18 percent to $956 million and 30 percent to $2.7 billion from the comparative prior-year periods, respectively. GAAP and non-GAAP operating earnings for the three and nine months ended March 31, 2026 were favorably impacted by increased contribution from branded and specialty pharmaceutical products, the impact of the acquisitions of management services organization ("MSO") platforms and Advanced Diabetes Supply Group ("ADS"), and the performance of our generics program.
Previous report
Solaris Health Acquisition
Previous report
On November 3, 2025, we, through The Specialty Alliance, completed the acquisition of Solaris Health, a urology MSO, for a purchase price of approximately $1.9 billion in cash, subject to certain adjustments. In connection with the closing of this transaction, we issued common units in The Specialty Alliance to certain physicians and members of management which are estimated to have a grant date fair value of approximately $500 million, a portion of which will be recognized as post-combination expense within acquisition-related cash and share-based compensation costs.
Previous report
Solaris Health includes more than 750 providers across more than 250 practice locations in 14 states. Solaris Health is part of The Specialty Alliance, our multi-specialty MSO platform, and their results are reported within our Pharma segment. With the closing of this transaction, we own approximately 76% of The Specialty Alliance. We funded the acquisition with a combination of cash proceeds from the recent debt financing and cash on hand. See Note 5 of the "Notes to Condensed Consolidated Financial Statements" for additional information on the debt financing.
Previous report
Management Service Organization Platforms
Previous report
The performance of our MSO platforms positively impacted the year-over-year comparison of Pharma segment profit during the three and nine months ended March 31, 2026, primarily due to the impact of the acquisitions of GI Alliance ("GIA"), Urology America, and Solaris Health. The Specialty Alliance is our multi-specialty MSO platform, which is primarily comprised of GIA, Urology America, Solaris Health and other gastroenterology- and urology-focused practices. Navista is our oncology MSO platform, which is primarily comprised of ION and other oncology-focused practices. Our ability to successfully provide physician practice support and management services, and to receive the value we expect to receive from our recent acquisitions of MSO platforms, depends upon a number of factors, including: the ability to develop or acquire and integrate appropriate practice management and support expertise; the ability to support recruitment, integration, and retention of sufficient numbers of local providers and staff; ensuring the alignment of interests between Cardinal Health and the physicians; the ability to successfully support negotiations with vendors, suppliers, and payors; the reimbursement and regulatory environment; and competition from other healthcare organizations.
Previous report
We have taken actions to reduce the impact of IEEPA and other tariffs on our financial results, including through cost optimization initiatives and by increasing prices on impacted products to customers; however, these measures have not fully offset the negative impact. As of the third quarter of fiscal year 2026, we have paid approximately $200 million in IEEPA tariffs, primarily related to products that we source, manufacture or distribute in our GMPD segment. In the event that we receive refunds of IEEPA tariffs from the government, we expect to return to those customers the portion of those refunds that reflect the estimated increased prices paid related to IEEPA tariffs.
Previous report
Following the Supreme Court IEEPA ruling, the U.S. government replaced IEEPA tariffs with tariffs imposed under Section 122 of the Trade Act of 1974. We continue to evaluate the impact of these and other tariffs, including tariffs imposed under Sections 301 and 232 of the Trade Act of 1974.
Previous report
Results of Operations
Previous report
Revenue
Previous report
Pharmaceutical and Specialty Solutions
Previous report
Pharma segment revenue for the three months ended March 31, 2026 increased 11 percent to $56.1 billion from the comparative prior-year quarter, primarily due to branded and specialty pharmaceutical sales growth from existing customers.
Previous report
Pharma segment revenue for the nine months ended March 31, 2026 increased 18 percent to $176.0 billion from the comparative prior-year period, primarily due to branded and specialty pharmaceutical sales growth from existing and new customers.
Previous report
GMPD segment revenue for the three months ended March 31, 2026 was flat at $3.1 billion compared to the prior-year quarter. This reflected lower distribution volumes, offset by Cardinal Health brand growth.
Previous report
GMPD segment revenue for the nine months ended March 31, 2026 increased 2 percent to $9.6 billion from the comparative prior-year period, primarily due to Cardinal Health brand growth, partially offset by lower distribution volumes.
Previous report
Other
Previous report
Other segment revenue for the three and nine months ended March 31, 2026 increased 31 percent to $1.7 billion and 34 percent to $5.1 billion from the comparative prior-year periods, respectively, due to growth across at-Home Solutions (including the acquisition of ADS), Nuclear and Precision Health Solutions, and OptiFreight® Logistics.
Previous report
Cost of Products Sold
Previous report
Cost of products sold for the three and nine months ended March 31, 2026 increased 11 percent to $58.4 billion and 17 percent to $183.4 billion from the comparative prior-year periods, respectively, primarily due to the factors affecting the changes in revenue and gross margin.
Previous report
Gross Margin
Previous report
Gross margin for the three and nine months ended March 31, 2026 increased 18 percent to $2.5 billion and 21 percent to $7.2 billion from the comparative prior-year periods, respectively, primarily due to the acquisitions of MSO platforms and ADS, increased contribution from branded and specialty pharmaceutical products, and the performance of our generics program.
Previous report
Gross margin rates for the three and nine months ended March 31, 2026 grew 23 basis points to 4.10 percent and 12 basis points to 3.79 percent from the comparative prior-year periods, respectively, primarily due to the acquisition of MSO platforms, partially offset by the impact of the unfavorable changes in product mix in the Pharma segment. These changes in product mix were primarily driven by increased pharmaceutical distribution branded sales, which have a dilutive impact on our overall gross margin rate.
Previous report
Distribution, Selling, General and Administrative ("SG&A") Expenses
Previous report
SG&A expenses for the three and nine months ended March 31, 2026 increased 17 percent to $1.5 billion and 16 percent to $4.5 billion from the comparative prior-year periods, respectively, primarily due to the acquisitions of MSO platforms and ADS.
Previous report
Segment Profit
Previous report
We evaluate segment performance based on segment profit, among other measures. See Note 12 of the "Notes to Condensed Consolidated Financial Statements" for additional information on segment profit.
Previous report
Pharmaceutical and Specialty Solutions
Previous report
Pharma segment profit for the three months ended March 31, 2026 increased 18 percent to $784 million from the comparative prior-year quarter, primarily due to increased contribution from branded and specialty pharmaceutical products and the performance of our generics program.
Previous report
Pharma segment profit for the nine months ended March 31, 2026 increased 24 percent to $2.1 billion from the comparative prior-year period, primarily due to increased contribution from branded and specialty pharmaceutical products, the acquisition of MSO platforms, and the performance of our generics program.
Previous report
Global Medical Products and Distribution
Previous report
GMPD segment profit for the three months ended March 31, 2026 decreased 36 percent to $25 million from the comparative prior-year quarter, primarily due to the adverse net impact of tariffs.
Previous report
GMPD segment profit for the nine months ended March 31, 2026 increased 66 percent to $108 million from the comparative prior-year period, primarily due to growth from existing customers, partially offset by the adverse net impact of tariffs.
Previous report
Other
Previous report
Other segment profit for the three and nine months ended March 31, 2026 increased 34 percent to $179 million and 47 percent to $524 million from the comparative prior-year periods, respectively, primarily due to the performance of at-Home Solutions (including the acquisition of ADS), OptiFreight® Logistics, and Nuclear and Precision Health Solutions.
Previous report
Corporate
Previous report
The changes in Corporate for the three and nine months ended March 31, 2026 were due to the factors discussed in the "Other Components of Consolidated Operating Earnings" section that follows.
Previous report
Other Components of Consolidated Operating Earnings
Showing the first 40 of 130 passages. Open the source sections for the rest.
Reworded paragraphs (11)
Previous wording
Global Medical Products and Distribution
Current wording
Global Medical Products and Distribution Segment
Previous wording
(1)Diluted earnings per share attributable to Cardinal Health, Inc. ("diluted EPS").
Current wording
(1) Diluted earnings per share attributable to Cardinal Health, Inc. ("diluted EPS").
Previous wording
(2)The reconciling items are presented within this table net of tax. See quantification of tax effect of each reconciling item in our GAAP to Non-GAAP Reconciliations in the "Explanation and Reconciliation of Non-GAAP Financial Measures."
Current wording
(2) The reconciling items are presented within this table net of tax. See quantification of tax effect of each reconciling item in our GAAP to Non-GAAP Reconciliations in the "Explanation and Reconciliation of Non-GAAP Financial Measures."
Previous wording
GAAP diluted EPS for the three months ended March 31, 2026 decreased 20 percent to $1.69 from the comparative prior-year quarter, primarily due to the factors impacting GAAP operating earnings discussed in the preceding section, partially offset by favorable changes in discrete tax items. GAAP diluted EPS for the nine months ended March 31, 2026 increased 2 percent to $5.54 from the comparative prior-year period, primarily due to the factors impacting GAAP operating earnings discussed in the preceding section and favorable changes in discrete tax items, partially offset by increased interest expense.
Current wording
GAAP diluted EPS for the three months ended September 30, 2026 increased 27 percent from the prior-year quarter to $2.38, primarily due to the factors impacting GAAP operating earnings in the preceding section and favorable changes in discrete tax items.
Previous wording
Non-GAAP diluted EPS for the three and nine months ended March 31, 2026 increased 35 percent to $3.17 and 36 percent to $8.35 from the comparative prior-year periods, respectively, primarily due to the factors impacting non-GAAP operating earnings discussed in the preceding section and favorable changes in discrete tax items, partially offset by increased interest expense.
Current wording
Non-GAAP diluted EPS for the three months ended September 30, 2026 increased 28 percent from the prior-year quarter to $3.26, primarily due to the factors impacting non-GAAP operating earnings in the preceding section and favorable changes in discrete tax items.
Previous wording
During the three and nine months ended March 31, 2026, we saw an increased demand for GLP-1 pharmaceuticals which positively impacted our Pharma segment and consolidated revenue for the three and nine months ended March 31, 2026; however, increased GLP-1 sales did not meaningfully contribute to segment profit. Future demand for these medications is unpredictable and our ability to meet demand may be impacted by supply constraints. Additionally, the recently issued Executive Order titled “Delivering Most-Favored Nation Prescription Drug Pricing to American Patients” and other administrative policies or actions may impact sales or profitability of branded pharmaceutical products; however, the extent of the impact is uncertain and may vary depending on the timeline for implementation and the extent of any price reductions.
Current wording
There are a number of proposed and adopted U.S. government policy initiatives being considered that could directly or indirectly impact pharmaceutical manufacturer list prices for branded pharmaceutical products. The Inflation Reduction Act has and will continue to adversely impact our revenue by capping prices for certain drugs; however, our profitability has not been materially impacted. Additionally, the Executive Order titled “Delivering Most-Favored Nation Prescription Drug Pricing to American Patients” and other administrative policies or actions may impact sales or profitability of branded pharmaceutical products. The extent of any future impacts is uncertain and may vary depending on the timeline for implementation and the extent of any price reductions.
Previous wording
The performance of our Pharma segment generics program positively impacted the year-over-year comparison of Pharma segment profit during the three and nine months ended March 31, 2026. The Pharma segment generics program includes, among other things, the impact of generic pharmaceutical product launches, customer volumes, pricing changes, the Red Oak Sourcing, LLC venture ("Red Oak Sourcing") with CVS Health Corporation ("CVS Health"), and generic pharmaceutical contract manufacturing and sourcing costs.
Current wording
The financial results of our Pharma segment generics program include, among other things, the impact of generic pharmaceutical product launches, customer volumes, pricing changes, the Red Oak Sourcing, LLC venture ("Red Oak Sourcing") with CVS Health Corporation ("CVS Health"), and generic pharmaceutical contract manufacturing and sourcing costs.
Previous wording
The frequency, timing, magnitude, and profit impact of generic pharmaceutical customer volumes, pricing changes, customer contract renewals, generic pharmaceutical manufacturer pricing changes, and generic pharmaceutical contract manufacturing and sourcing costs all impact Pharma segment profit and are subject to risks and uncertainties. These risks and uncertainties may impact Pharma segment profit and consolidated operating earnings during the remainder of fiscal 2026 and beyond.
Current wording
The frequency, timing, magnitude, and profit impact of generic pharmaceutical customer volumes, pricing changes, customer contract renewals, generic pharmaceutical manufacturer pricing changes, and generic pharmaceutical contract manufacturing and sourcing costs all impact Pharma segment profit and are subject to risks and uncertainties. Additionally, while generic pharmaceutical products are not currently subject to U.S. tariffs, it is possible that this may change in the future, which may impact our costs or decrease available supply. These risks and uncertainties may impact Pharma segment profit and consolidated operating earnings during the remainder of fiscal 2027 and beyond.
Previous wording
In February 2025, the United States imposed tariffs under the International Emergency Economic Powers Act ("IEEPA") on certain goods, materials and products imported into the United States from countries where we do business. In February 2026, the U.S. Supreme Court ruled that the IEEPA tariffs were unlawful but did not establish a mechanism for issuing refunds. Subsequent to this ruling, U.S. Customs and Border Protection ("CBP") worked to establish a phased process to administer refunds required by the Supreme Court ruling; however, uncertainty remains concerning the timing, scope and administrative process to receive refunds for all IEEPA tariffs paid. In April 2026, CBP launched its program to administer Phase 1 refund requests; however, substantially all of our IEEPA tariffs paid will fall under Phase 2 or later phases. As of the date hereof, CBP has not communicated a date on which the refund process for such Phase 2 or later phases will be established or available.
Current wording
In February 2026, the U.S. Supreme Court ruled that the IEEPA tariffs were unlawful. Subsequent to this ruling, U.S. Customs and Border Protection (the "CBP") worked to establish a phased process to administer refunds required by the Supreme Court ruling. In April 2026 and June 2026, the U.S. Government launched its program to administer refund requests under Phase 1 and Phase 2, respectively, and additional phases are expected to be communicated in the future. The majority of our refund requests fall under Phase 2. Our refund requests under Phases 1 and 2 have been submitted and accepted by the CBP. We expect that the remainder of our refund requests will be submitted in later phases or through other established mechanics.
Previous wording
We have not recognized any financial impact related to potential tariff refunds or payments to our customers as of March 31, 2026. The ultimate resolution of this matter could positively impact our results of operations in future periods, including GMPD segment profit and consolidated operating income.
Current wording
As of September 30, 2026, we have recovered the majority of refunds for the claims submitted under Phase 1 and Phase 2. We expect the remainder of claims to be submitted in future phase filings, for which the CBP has not yet opened the claims submission process. After receiving refunds of all IEEPA tariffs from the U.S. Government, we expect to return to customers the portion of those refunds that reflect the estimated increased prices paid related to IEEPA tariffs. The ultimate resolution of this matter could impact our results of operations in future periods, including GMPD segment profit and consolidated operating income.
Previous wording
Tariff rates remain dynamic and we do not expect to be able to establish alternative sources of supply or otherwise mitigate the potential impact of tariffs on all of the products that we source, manufacture or distribute. We are still incurring increased costs from tariffs, and if we are not successful at increasing prices to customers, our financial results will continue to be negatively impacted. Additionally, if tariffs are modified in the future, or our information is incorrect regarding their impact, we may not be able to respond to such changes adequately or in a timely manner and our financial results could be negatively impacted. Furthermore, if our competitors do not increase prices, or increase prices to a lesser extent than we do or are able to offset the impact of tariffs through other actions, our competitive and financial position may be adversely affected.
Current wording
The tariff environment remains dynamic and we do not expect to be able to establish alternative sources of supply or otherwise mitigate the potential impact of tariffs on all of the products that we source, manufacture, or distribute. For example, in addition to the IEEPA tariffs discussed above, our GMPD segment has experienced, and expects to continue to experience, increased costs as a result of tariffs imposed or expected to be imposed under different legal authority. Our GMPD segment continues to take action to reduce the impact of these and other potential tariffs on our financial results, including through cost optimization initiatives and by increasing prices on impacted products to customers; however, these measures have not fully offset the adverse impact and may not in the future. We are still incurring increased costs from tariffs, and if we are not successful at increasing prices to customers, our financial results will continue to be negatively impacted. Furthermore, if our competitors do not increase prices, or increase prices to a lesser extent than we do or are able to offset the impact of tariffs through other actions, our competitive and financial position may be adversely affected.
Rearranged current paragraphs (2)
Current report — wording carried from elsewhere
International Emergency Economic Powers Act ("IEEPA") Tariffs
Current report — wording carried from elsewhere
In February 2025, the United States imposed tariffs under the IEEPA on certain goods, materials, and products imported into the United States from countries where we do business. Between February 2025 and 2026, we have paid approximately $200 million in IEEPA tariffs, related to products that we source, manufacture, or distribute, primarily in our GMPD segment.
Rearranged previous paragraphs (4)
Previous report — wording carried elsewhere
Explanation and Reconciliation of Non-GAAP Financial Measures
Previous report — wording carried elsewhere
Explanation and Reconciliation of Non-GAAP Financial Measures
Previous report — wording carried elsewhere
Explanation and Reconciliation of Non-GAAP Financial Measures
Previous report — wording carried elsewhere
Explanation and Reconciliation of Non-GAAP Financial Measures